Who is sponsoring NCT05946824?

NCT05946824 is sponsored by University of Rochester.

What drugs are being tested in NCT05946824?

Interventions in NCT05946824: Daily-adaptive Stereotactic Body Radiation Therapy, Daily-adaptive Stereotactic Body Radiation Therapy.

What condition does NCT05946824 study?

NCT05946824 studies Recurrent Prostate Cancer After Surgery.

Is NCT05946824 still recruiting?

NCT05946824 is currently recruiting now. Last updated 8 October 2024.

Last reviewed 2024-10-08 · How we verify

NCT05946824: DASBRT-RPC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.

Recruiting now Phase 2 Last updated 8 October 2024

What this trial tests

Phase 2 trial testing Daily-adaptive Stereotactic Body Radiation Therapy in Recurrent Prostate Cancer After Surgery in 80 participants. Currently enrolling.

Timeline

14 December 2023

Primary endpoint
24 November 2025

24 November 2028

Quick facts

Lead sponsor	University of Rochester
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	14 December 2023
Primary completion	24 November 2025
Estimated completion	24 November 2028
Sites	1 location across United States

Drugs / interventions tested

Daily-adaptive Stereotactic Body Radiation Therapy
Daily-adaptive Stereotactic Body Radiation Therapy

Conditions studied

Recurrent Prostate Cancer After Surgery — all drugs for Recurrent Prostate Cancer After Surgery →

Sponsor

University of Rochester

Who can join

18 and older, male only, with Recurrent Prostate Cancer After Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the health care system. Stereotactic body radiation (SBRT) is a radiation technique in which large doses are delivered over a short period of time. To date there is extremely limited evidence in SBRT for recurrent prostate cancer after surgery, with a significantly growing body of evidence for primary SBRT treatment of prostate cancer in men who opt for non-surgical upfront treatment. Additionally, advances in imaging have allowed better detection of the site of recurrence, and novel artificial intelligence aided daily-adaptive radiation therapy have allowed more precise delivery of radiation doses. This study seeks to evaluate the role of Daily-Adaptive with AI-assisted SBRT in the post operative setting utilizing Ethos Plan Adaptive technology in attempt to maintain control and minimize side effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tribulations and future opportunities for artificial intelligence in precision medicine.
Carini C, Seyhan AA. · · 2024 · cited 67× · PMID 38702711 · DOI 10.1186/s12967-024-05067-0

Verify or expand the search:

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05946824 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 8 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05946824.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing